Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon

  • Viswanath Ragupathy1,

    Affiliated with

    • Jiangqin Zhao1,

      Affiliated with

      • Owen Wood1,

        Affiliated with

        • Shixing Tang1,

          Affiliated with

          • Sherwin Lee1,

            Affiliated with

            • Phillipe Nyambi2 and

              Affiliated with

              • Indira Hewlett1Email author

                Affiliated with

                Virology Journal20118:185

                DOI: 10.1186/1743-422X-8-185

                Received: 3 November 2010

                Accepted: 23 April 2011

                Published: 23 April 2011

                Abstract

                Background

                The HIV epidemic in Cameroon is characterized by a high degree of viral genetic diversity with circulating recombinant forms (CRFs) being predominant. The goal of our study was to determine recent trends in virus evolution and emergence of drug resistance in blood donors and HIV positive patients.

                Methodology

                Blood specimens of 73 individuals were collected from three cities and a few villages in Cameroon and viruses were isolated by co-cultivation with PBMCs. Nested PCR was performed for gag p17 (670 bp) pol (840 bp) and Env gp41 (461 bp) genes. Sequences were phylogenetically analyzed using a reference set of sequences from the Los Alamos database.

                Results

                Phylogenetic analysis based on partial sequences revealed that 65% (n = 48) of strains were CRF02_AG, 4% (n = 3) subtype F2, 1% each belonged to CRF06 (n = 1), CRF11 (n = 1), subtype G (n = 1), subtype D (n = 1), CRF22_01A1 (n = 1), and 26% (n = 18) were Unique Recombinant Forms (URFs). Most URFs contained CRF02_AG in one or two HIV gene fragments analyzed. Furthermore, pol sequences of 61 viruses revealed drug resistance in 55.5% of patients on therapy and 44% of drug naïve individuals in the RT and protease regions. Overall URFs that had a primary HIV subtype designation in the pol region showed higher HIV-1 p24 levels than other recombinant forms in cell culture based replication kinetics studies.

                Conclusions

                Our results indicate that although CRF02_AG continues to be the predominant strain in Cameroon, phylogenetically the HIV epidemic is continuing to evolve as multiple recombinants of CRF02_AG and URFs were identified in the individuals studied. CRF02_AG recombinants that contained the pol region of a primary subtype showed higher replicative advantage than other variants. Identification of drug resistant strains in drug-naïve patients suggests that these viruses are being transmitted in the population studied. Our findings support the need for continued molecular surveillance in this region of West Central Africa and investigating impact of variants on diagnostics, viral load and drug resistance assays on an ongoing basis.

                Introduction

                HIV/AIDS was first identified in Cameroon during 1985 [1] and the epidemic has continued to increase with the identification of multiple, divergent HIV subtypes and circulating recombinant forms (CRFs) [2]. According to a recent epidemiological surveillance report, 10,625 new infections were diagnosed in Cameroon during 2007 in comparison with 8,596 new infections during 2006 [3]. Furthermore, about 5.1% (ages 15-49) of adults are living with HIV/AIDS; among them, 60% (ages 15-49) were women. The majority of HIV infections in Cameroon are due to heterosexual transmission and high rates (40-50%) of infection have been observed among risk groups such as commercial sex workers and long distance truck drivers (UNAIDS/WHO) [4]. Antiretroviral therapy (ART) was initiated in Cameroon during 2001 and later decentralized to district level hospitals by the WHO 3by5 initiative (treating 3 million by 2005). In a study from Yaounde, Cameroon it was reported that 2.6% protease drug resistance and 9.3% major reverse transcriptase drug resistance were detected among patients who never received therapy, a finding that has implications for the efficacy of first line therapies [5]. Further in a study conducted at Doula, Cameroon [6] out of 819 patients who received first line ART, 36% had virological failure after 6 months or more. About 80% of drug resistance was detected for Nucleoside Reverse Transcriptase Inhibitors (NRTI) class, followed by the non-nucleoside reverse transcriptase Inhibitors (NNRTI) (76%) and Protease Inhibitor (PI) class (19%) drugs.

                HIV infection in Cameroon is characterized by highly diversified strains including Circulatory Recombinant Forms (CRFs), Group O and N [7] which pose a challenge for diagnosis, vaccines and treatment [8]. Recently a new HIV strain, group P of gorilla origin, was identified in a Cameroonian woman [9] and shown to be distinct from other HIV groups O and N identified earlier in Cameroon [10, 11]. Although new strains have been shown to emerge in Cameroon, studies that analyzed three immunodominant regions gag/pol/env have documented that 60-70% of infections continue to be CRF02_AG [12, 13]. The current HIV molecular epidemic in Cameroon is predominantly based on CRF02_AG (65-75%), pure subtypes A1, A2, C, F2, G and H(1-5%), 6 different CRFs (-01, -11, -13, -18, -25, -37), divergent forms group O (2.2-3.8%) and HIV-2 (0.4-1.2%) [1315]. Several previous reports on molecular epidemiology in Cameroon were from urban area using phylogenetic analysis of only gag and env gene sequences. In the first study it was reported that CRF02_AG accounted for 60%, followed by URFs(26%), 12 pure subtypes and CRFs [16] and in another study CRF02_AG accounted for 58.2% of infections followed by 14.8% of URFs, 0.2 - 6.1% of subtypes, A, B, C, D, F2, G and CRFs 01, 06, 09, 11, 13, 22, and 37 [12]. Both studies confirmed CRF02_AG is a dominant strain in urban Cameroon. However rural Cameroon comprises the majority of the country's population and in certain rural areas HIV prevalence has been found to be double the national rate (8-10%) [17]. In recent studies from rural Cameroon, CRF02_AG was shown to be a dominant strain 66.5% whether analyzed from a single pol fragment [14] or individual fragments of gag (65%), pol (75%) and env (55%) [13] followed by a second dominant strain CRF22_01_A1 in 5-10% of infections [14, 18]. CRF22_01_A1 had been detected earlier [19] as a URF and later by full genome sequencing in two studies [14, 18] and was found to be 2nd dominant circulating strain in Cameroon. It is interesting to note that along with these subtypes and CRFs about 10-20% of strains were unique recombinant forms (URFs) that were likely generated by recombination of existing strains [12, 19].

                CRF02_AG recombinant viruses have become well established in the Cameroonian population possibly due to a founder effect from parent strains subtype A [20.21] and G [22] and/or a higher replicative advantage of CRF02_AG over other co-circulating recombinants [23, 24]. A prospective study confirmed that CRF02_AG is the predominant strain in blood donors in Yaoundé, Cameroon [12]; however, other CRFs and Unique Recombinant Forms (URFs) have also been detected [2527]. The ongoing evolution of HIV and emergence of new recombinant forms are a major concern for the global AIDS pandemic. Several factors may contribute to the emergence of recombinant viruses or URFs but most importantly, recombination provides a mechanism to increase viral sequence diversity rapidly, unlike the slow accumulation of mutations that occurs through replication errors [28]. For recombination to occur between distinct HIV-1 strains, a cell needs to be dually infected with different viruses the progeny virions that result possess RNA genomes from each virus, permitting strand-switching to occur during the next round of reverse transcription. Therefore, recombination requires co-infection of viral strains in an individual. This dual infection may occur during the primary infection period, before the immune response is fully developed, or it may occur as a superinfection with a new viral strain after the initial strain has established a chronic infection. Super infection with a different strain is thought to be the most predominant contributor to viral recombination [29]. The possibility for superinfection among high risk individuals has been reported in Cameroon [30]. Both superinfection and recombination have the potential to complicate efforts to develop vaccines, and reinfection with a drug-resistant virus could jeopardize available treatment options. To date 49 CRFs have been identified [31] and recombination between the URFs and existing CRFs results in Second Generation Recombinants (SGRs) [27] which would further complicate the phylogenetic nature of the epidemic. In the present study we have analyzed recent trends in the genetic evolution of the HIV epidemic in different regions of Cameroon and demonstrated the ongoing emergence of new recombinants and prevalence of multi-drug resistant viruses in the population.

                Materials and methods

                Study Population

                Blood samples were received from blood banks and clinics in 3 cities in Cameroon (Figure 1), samples from blood banks were from Bamenda (ARC) (n = 28) in the North West and other clinical sites at Buea (BDHS) (n = 21), Limbe (LPH) (n = 16) in the South West and a few villages in Cameroon (NYU) (n = 8). Demographic information was collected in the performa. The specimens used for this study had all been previously obtained for another purpose and were de-identified for the analysis.
                http://static-content.springer.com/image/art%3A10.1186%2F1743-422X-8-185/MediaObjects/12985_2010_1353_Fig1_HTML.jpg
                Figure 1

                Samples for this study were collected from Bamenda, Buea and Limbe in Cameroon are indicated with an asterisk (*).

                Virus culture, polymerase chain reaction (PCR) and sequencing

                Seventy three viruses were cultured in peripheral blood mononuclear cells (PBMCs) of buffy coat received from HIV seronegative blood donors from the NIH Blood bank. Viruses were propagated as per our standard protocol of the laboratory published earlier [32]. Cell free viruses were harvested and stored frozen at -80°C. Viral RNA was isolated using the QIAGEN viral RNA kit (Cat: 52906) and complementary DNA was synthesized in a 20 ul reaction using Invitrogen Superscript III RT kit (Cat: 18080-051) and custom primers BOA (HXB2 coordinate 5242-5267) and DOAR (HXB2 coordinate 9513-9538). Briefly, reaction conditions were 65°C for 5 min with template and 10 mM dNTP mix, followed by 50°C for 50 min with RT reagents and two fragments of cDNA was synthesized from the template RNA. Nested PCR reaction was performed for Gp41 (461 bp), p17 (670 bp) of all 73 isolates and 61 viruses for pol (840 bp) region. The reaction mixture consisted of PCR pre mix buffer from Invitrogen (Cat No: M7505), 25 pmole of each primer (Table 1) for both the rounds of PCR and reaction conditions were one cycle at 94°C for 3 min, 30 cycles at 94°C for 30 s, 50°C for 30 s, 72°C for 1.2 min and final extension 72°C for 7 minutes. Amplified products were detected by 1% agarose gel electrophoresis. All PCR fragments were sequenced by ABI dye terminator reaction systems.
                Table 1

                List of PCR primers used for amplification of gp41, p17 and pol genes of HIV.

                Gene

                Primer

                Reaction

                Sequence

                HXB2 coordinates

                Size in bp

                gp41*

                gp40F1

                gp41R1

                1st PCR

                TCTTAGGAGCAGCAGGAAGCACTATGGG

                AACGACAAAGGTGAGTATCCCTGCCTAA

                7840-8300

                461

                 

                gp46F2

                gp47R1

                2nd PCR

                ACAATTATTGTCTGGTATAGTGCAACAGCA

                TTAAACCTATCAAGCCTCCTACTATCATTA

                  

                p17*

                pL393 pL392

                1st PCR

                AAGGGTACTAGTAGTTCCTGCTATG

                GCTGAAGCGCGCACGGCAAGAG

                761-1437

                670

                 

                p17-1033

                p17-1048

                2nd PCR

                TCTATCCCATTCTGCAGCTTCCTCATTGAT

                TTTGACTAGCGGAGGCTAGA

                  

                pol

                ANA corr

                SP5R

                1st PCR

                CAGGAGCAGATGATACAGTATTAG

                ATTTATCAGGATGGAGTTCA

                2390-3229

                840

                 

                AOA Corr

                SP5F-r

                2nd PCR

                GATAGGGGGAATTGGAGG

                AATGGAGGTTCTTTCTGATGT

                  

                * These primer sets were shown to amplify nucleic acid from Cameroonian viruses efficiently in previous studies [13].

                Sequence Analysis

                A phylogenetic analysis was performed using partial genome segments and analyzed by the MEGA 4.1 software package. Pair wise evolutionary distances were generated using Kimura's two-parameter method; major gaps in the alignment were masked out prior to analysis and phylogenetic trees were constructed by neighbor-joining [33, 34]. Nucleotide sequences were aligned by the Clustal W program [34] using partial curated alignments of 42 CRFs and inter-subtypes as reference sequences. All reference subtypes and CRFs were obtained from the Los Alamos HIV Sequence Database and initially used to construct the trees [31]. Some references have been omitted during the analysis for clarity and all positions with alignment gaps were removed. Confidence values for individual branches have been determined using bootstrap analysis.

                The 840 bp (Hxb2 position 2390-3229) genomic region studied for reverse transcriptase (codon 1-227) and protease drug (codon 46-99) resistance may not represent the entire profile of drug associated mutations. However this paper analyzed 80% of the protease and the entire RT region of the pol gene. HIV drug resistance was analyzed using the Stanford University HIValg Program [compares three programs HIVdb, Rega Institute and Agence Nationale de Recherches surle SIDA (ANRS)]. The 61 pol sequences were analyzed for mutations associated with NRTI, NNRTI and PI drug resistance using the HIValg program available on the Stanford University HIV Drug Resistance Database website [35]. Mutations in the sequences were defined as differences from the consensus B reference sequence and were further characterized as NRTI-resistance mutations, NNRTI-resistance mutations, PI-resistance mutations or other mutations which consists primarily of accessory mutations (those which alone or have little or no effect on drug susceptibility) and polymorphisms. For each sequence analyzed, the drug resistance interpretation was compared for consistency and only consistent mutations in 2 or more algorithms predicted are presented in the Table. Since data generated from 61 viruses was too large for inclusion in the manuscript it has been summarized in the form of a Table (data sheets may be provided for individual requests).

                Sequence Information

                The sequences generated for this study are available from GenBank under the accession numbers for p17 (FJ014614-FJ014646); gp41 (FJ014673-FJ014703); pol (FJ014647-FJ014672).

                Results

                The demographics in terms of gender, age and route of HIV acquisition are outlined below. Seventy three samples obtained from 59 females and 14 males were analyzed in this study. The ages of men and women were 35-55 and 16-59 years respectively. Heterosexual contact accounted for 94% of infections and 6% reported having no extramarital relations but had received blood transfusions. Out of 61 patients, 18 (29%, 11 female and 7 male) reported having received therapy (3by5 initiated by WHO); the other 43 (71%, 5 men and 38 women) were drug naïve.

                Out of 73 samples, PCR was successful for 72 samples in the p17 (gag), 70 samples in the gp41 (env) regions and 61 samples in the pol region. Genotyping analysis of the p17 region revealed that 75% were CRF0_2AG, 7% were CRF11 and F2, 3% were subtype CRF22_01A1, D, B and 1% was CRF06, and subtype G (Table 2). The pol region analysis revealed that 74% were CRF02_AG, 5% were subtype F2 and CRF22_01A1, 3% were CRF01_AE and subtype D, 2% were comprised of CRF06, CRF 11, CRF09, B and G (Table 2). Gp41 genotyping revealed that 79% were CRF02_AG, 6% were subtype F2, 7% were CRF22_01A1, 3% were CRF11 and G, 1% was subtype D and CRF06 (Table 2). Based on sequence analysis of 2 or 3 distinct genes, HIV genotypes circulating in Cameroon were found to be CRF02_AG (65%), URFs (26%) subtype F2 (4%) and 1% each of CRF06, CRF11, CRF22_01A1, subtype G and D (Figure 2). Phylogenetic analyses are assessed from enclosed additional file 1.
                Table 2

                Partial Genotypes based on p17/pol/gp41 genes of HIV for samples from Cameroon

                Sample ID

                Gag(p17)

                pol

                Env(gp41)

                Genotype

                06CMARC009

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMARC010

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMARC011

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMARC023

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMARC036

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMARC053

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMARC058

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMLPH016SL

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMLPH17HT

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMLPH03VJ

                CRF02

                CRF02

                Not Done

                CRF02_AG

                06CMLPH22NH

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMLPH20SL

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMLPH02MG

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMLPH05DE

                CRF02

                CRF02

                CRF02

                CRF02_AG

                07CMLPH128

                CRF02

                CRF02

                Not Done

                CRF02_AG

                06CMARC001

                CRF02

                Not done

                CRF02

                CRF02_AG

                06CMARC004

                CRF02

                Not done

                CRF02

                CRF02_AG

                06CMARC006

                CRF02

                Not done

                CRF02

                CRF02_AG

                06CMARC065

                CRF02

                Not done

                CRF02

                CRF02_AG

                06CMARC066

                CRF02

                Not done

                CRF02

                CRF02_AG

                06CMARC067

                CRF02

                Not done

                CRF02

                CRF02_AG

                06CMARC068

                CRF02

                Not done

                CRF02

                CRF02_AG

                06CMARC069

                CRF02

                Not done

                CRF02

                CRF02_AG

                BDHS 131

                CRF02

                CRF02

                CRF02

                CRF02_AG

                BDHS 139

                CRF02

                CRF02

                CRF02

                CRF02_AG

                NYU 707

                CRF02

                CRF02

                CRF02

                CRF02_AG

                NYU 871

                CRF02

                CRF02

                CRF02

                CRF02_AG

                NYU 997

                CRF02

                CRF02

                CRF02

                CRF02_AG

                NYU 1003

                CRF02

                CRF02

                CRF02

                CRF02_AG

                ARC 152

                CRF02

                CRF02

                CRF02

                CRF02_AG

                ARC 155

                CRF02

                CRF02

                CRF02

                CRF02_AG

                ARC 097

                CRF02

                CRF02

                CRF02

                CRF02_AG

                BDHS 09

                CRF02

                CRF02

                CRF02

                CRF02_AG

                BDHS12

                CRF02

                CRF02

                CRF02

                CRF02_AG

                ARC 88

                CRF02

                CRF02

                CRF02

                CRF02_AG

                ARC 140

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06BDHS18

                CRF02

                CRF02

                CRF02

                CRF02_AG

                BDHS 28

                CRF02

                CRF02

                CRF02

                CRF02_AG

                BDHS 35

                CRF02

                CRF02

                CRF02

                CRF02_AG

                BDHS 52

                Not done

                CRF02

                CRF02

                CRF02_AG

                BDHS 56

                CRF02

                CRF02

                CRF02

                CRF02_AG

                LPH21MJ

                CRF02

                CRF02

                CRF02

                CRF02_AG

                NYU 474

                CRF02

                CRF02

                CRF02

                CRF02_AG

                LPH09OR

                CRF02

                CRF02

                CRF02

                CRF02_AG

                NYU 477

                CRF02

                Not done

                CRF02

                CRF02_AG

                NYU 807

                CRF02

                CRF02

                CRF02

                CRF02_AG

                07CMBDHS064

                CRF02

                CRF02

                CRF02

                CRF02_AG

                06CMARC013

                CRF06

                CRF06

                CRF06

                CRF06 cpx

                BDHS 138

                CRF22_01A1

                CRF22_01A1

                CRF22_01A1

                CRF22_01A1

                07BDHS 018

                CRF 11

                Not done

                CRF 11cpx

                CRF 11 cpx

                BDHS 132

                F2

                F2

                F2

                F2

                06CMBDHS019

                F2

                F2

                F2

                F2

                BDHS 36

                F2

                Not done

                F2

                F2

                BDHS 13

                D

                D

                D

                D

                LPH28AF

                G

                G

                G

                G

                LPH24OM

                CRF02

                CRF02

                CRF22_01A1

                URF

                06CMARC007

                B

                CRF02

                CRF02

                URF

                ARC 92

                CRF 11

                CRF02

                Not Done

                URF

                06CMARC031

                B

                B

                CRF02

                URF

                06CMARC055

                D

                D

                CRF02

                URF

                06CMLPH01OJ

                CRF02

                CRF09

                CRF02

                URF

                06CMBDHS05

                CRF02

                CRF11

                CRF02

                URF

                06CMBDHS07

                CRF 11

                CRF02

                CRF 11

                URF

                06CMBDHS024

                F2

                CRF02

                F2

                URF

                06CMLPH11TT

                CRF 11

                CRF01_AE

                CRF02

                URF

                06CMLPH19CM

                CRF 11

                CRF01_AE

                CRF02

                URF

                06CMARC071

                CRF22_01A1

                Not done

                CRF02

                URF

                06CMARC076

                F2

                Not done

                CRF02

                URF

                BDHS 25

                CRF02

                CRF02

                G

                URF

                NYU 488

                CRF02

                CRF02

                CRF22_01A1

                URF

                BDHS 33

                CRF02

                F2

                CRF02

                URF

                LPH27MF

                CRF02

                CRF22_01A1

                CRF22_01A1

                URF

                ARC 87

                CRF02

                CRF22_01A1

                CRF22_01A1

                URF

                http://static-content.springer.com/image/art%3A10.1186%2F1743-422X-8-185/MediaObjects/12985_2010_1353_Fig2_HTML.jpg
                Figure 2

                The Pie diagram shows the distribution of pure HIV subtypes and URFs. Discordant subtypes of URFs in the gag (p17), pol and Env (gp41) are indicated in the table.

                The replication kinetics of CRF02_AGs and URF strains were classified as fast, slow and no growth viruses. For the analysis, viruses that produced concentrations of HIV p24 >10-100 ng/ml at Day 7 were classified as fast growing viruses and those <10 or 0 ng/ml as slow or non replicating viruses. In the present study, p24 antigen levels in CRF02_AG cultures were 50.5 ng/ml at day 7 (Figure 3A) while levels in CRF02_AG containing URFs were 16.1 ng/ml (Figure 3B). Slow viruses had 3.6 to 0.1 ng/ml of p24 levels in the culture supernatants at day 7. Further more, slow growing viruses showed an increase of 1-2 ng of p24 at day 14 and 21, however some viruses showed no p24 increases during the culture period and hence were classified as non replicating viruses.
                http://static-content.springer.com/image/art%3A10.1186%2F1743-422X-8-185/MediaObjects/12985_2010_1353_Fig3_HTML.jpg
                Figure 3

                Figure 3A and 3B are histogram representations of the average HIV-1 p24 levels of CRF02_AG and URFs in cell culture studies.

                Of 61 viruses sequenced for HIV-1 drug resistance mutations, 18 had received antiretroviral therapy and 43 were drug naïve. Among the group that received antiretroviral therapy (ART), 8 viruses (44%) showed no drug-specific mutations, while 10 (55.5%) had drug-specific mutations in the RT and protease regions. Two ART patients harbored viruses with multi drug resistance for NNRTI/NRTI and 3 had low to high level mutations for NRTI/NNRTI. Interestingly 44% (19/43) of drug naïve patients were found to have one or more drug specific mutations in the RT and protease regions. However, only 42% (8/19) of mutations were those that confer drug resistance (Table 3), and 26% (11/43) of mutations were polymorphisms in the RT region. The impact of these polymorphisms for effective therapy of these patients is unknown.
                Table 3

                Drug sensitivity and resistance mutations in the reverse transcriptase and protease regions.

                Sample ID

                ARV Therapy

                RT Resistance

                Protease Resistance

                Genotype

                06CMARC010

                No

                Sensitive

                Sensitive

                CRF02_AG

                06CMARC011

                Yes

                --

                --

                CRF02_AG

                06CMARC031

                Yes

                --

                --

                URF

                06CMARC053

                Yes

                --

                --

                CRF02_AG

                06CMARC055

                Yes

                --

                --

                URF

                06CMARC058

                Yes

                --

                --

                CRF02_AG

                06CMLPH02MG

                No

                --

                --

                CRF02_AG

                06CMLPH05DE

                No

                --

                --

                CRF02_AG

                06CMLPH03VJ

                No

                --

                --

                CRF02_AG

                06CMLPH11TT

                No

                --

                --

                URF

                06CLPH16SL

                Yes

                --

                --

                CRF02_AG

                07CMLPH128

                Yes

                --

                --

                CRF02_AG

                06CMBDHS07

                Yes

                --

                --

                URF

                06CMLPH22NH

                No

                --

                --

                CRF02_AG

                06CMLPH01OJ

                No

                --

                --

                URF

                NYU 707

                No

                --

                --

                CRF02_AG

                ARC 155

                No

                --

                --

                CRF02_AG

                BDHS12

                No

                --

                --

                CRF02_AG

                06BDHS18

                No

                --

                --

                CRF02_AG

                BDHS 28

                No

                --

                --

                CRF02_AG

                LPH21MJ

                No

                --

                --

                CRF02_AG

                LPH24OM

                No

                --

                --

                URF

                ARC 097

                No

                --

                --

                CRF02_AG

                ARC 93

                No

                --

                --

                CRF02_AG

                BDHS 25

                No

                --

                --

                URF

                NYU 807

                No

                --

                --

                CRF02_AG

                NYU 474

                No

                --

                --

                CRF02_AG

                NYU 488

                No

                --

                --

                URF

                LPH27MF

                No

                --

                --

                URF

                BDHS 132

                No

                --

                --

                F2

                BDHS 13

                No

                --

                --

                D

                LPH28AF

                No

                --

                --

                G

                06CMBDHS05

                Yes

                A62V, V75I, F77L, F116Y, Q151M, M184V, Y188L

                A62V, K65R, T69I, V75I, V108I, F116Y, Q151M,

                --

                URF

                06CMARC007

                Yes

                Y181C, M184I

                --

                URF

                06CMARC036

                Yes

                K103N, V179E, Y181C, M184V, G190A

                --

                CRF02_AG

                06CMARC009

                Yes

                V179E

                --

                CRF02_AG

                06CMLPH17HT

                Yes

                G190A

                --

                CRF02_AG

                07CMBDHS064

                Yes

                G190A

                --

                CRF02_AG

                06CMARC023

                Yes

                L100Q, V108I

                --

                CRF02_AG

                ARC 88

                Yes

                D67N, T69N, K70R, L100I, K103N, M184V

                --

                CRF02_AG

                ARC 140

                Yes

                D67N, T69N, K70R, L100I, K103N, M184V

                --

                CRF02_AG

                ARC 87

                Yes

                T69I

                --

                URF

                06CMLPH20SL

                No

                V108I, F116Y, Q151M, Y181C, M184V

                --

                CRF02_AG

                LPH 09OR

                No

                K219Q

                --

                CRF02_AG

                ARC 152

                No

                V179E

                --

                CRF02_AG

                06CMLPH19CM

                No

                V118I

                --

                URF

                06CMBDHS024

                No

                G190A

                --

                URF

                06CMBDHS019

                No

                V108I, Y181C, M184V

                --

                F2

                06CMARC013

                No

                V179E

                --

                CRF06_cpx

                BDHS 52

                No

                H221K

                I54L

                CRF02_AG

                BDHS 35

                No

                V106L + D67H, V75L

                50S

                CRF02_AG

                BDHS 56

                No

                K219R

                --

                CRF02_AG

                BDHS 131

                No

                V90I

                --

                CRF02_AG

                BDHS 139

                No

                Y188F, Q151P, L210P

                --

                CRF02_AG

                NYU 871

                No

                V90I

                --

                CRF02_AG

                NYU 997

                No

                T215A

                --

                CRF02_AG

                NYU 1003

                No

                V106I

                --

                CRF02_AG

                BDHS 09

                No

                L100I, Y181I

                --

                CRF02_AG

                ARC 92

                No

                Q151R, V179D, G190R

                --

                URF

                BDHS 33

                No

                E44D, K19T, H221K

                --

                URF

                BDHS 138

                No

                T69I, l74f, A98G, E138A

                --

                CRF22_01A1

                Drug resistance mutation detected in patients on therapy and drug naïve are highlighted bold. Patient samples having polymorphisms at drug resistance codons are highlighted bold in last section.

                Among persons who showed primary drug resistance mutations, one patient (06CMLPH20SL) had multi drug resistance mutations for NNRTI/NRTI; two other patients (BDSH 35 and BDSH 52) had protease drug point mutations of I54L, which confers low level resistance for several protease drugs except tipranavir, and I50S, which is a polymorphism (Table 3). Furthermore, these individuals had NNRTI associated mutations in H221K/V106L/D67H and V75L, however these mutations were classified as polymorphisms. Three other patient viruses had point mutations for EFV/DLV/3TC/NVP or Etravirine and two patients had the K219R/Q Zidovudine (AZT) point mutation (Table 3).

                Since significant percentages (26%) of viral strains were found to be URFs, we analyzed the three genomic regions of HIV independently to determine phylogenetic associations between the URFs and other strains in the regions studied. Interestingly, two pairs of p17/pol/gp41 sequences phylogenetically clustered with high bootstrap 97-99% values (Table 4). One pair of sequences (06CMLPH19CM; 06CMLPH11TT) clustered 99% in the p17/pol/gp41. However, a second pair (06CMBDHS024; 06CMBDHS019) clustered only in the p17 and gp41 region. The pol gene of 06CMBDHS024 clustered with the pol gene of 06CMLPH17HT. Since both patients had distinct genotypes, the resulting genotype of 06CMBDHS024 was a URF (Table 4). Such associations were not observed with partial sequences from other patients analyzed.
                Table 4

                Phylogenetic association of patient isolates.

                Sample ID

                Sex

                Mode of Transmission

                Place

                Bootstrap

                Gag-p17

                Pol

                Env-gp41

                Genotype

                Gag Sequences (p17)

                        

                06CMBDHS019

                F

                Hx.Sex

                Buea

                100%

                F2

                F2

                F2

                F2

                06CMBDHS024

                F

                Hx.Sex

                Buea

                 

                F2

                CRF02

                F2

                URF*

                06CMLPH11TT

                F

                Hx. Sex

                Limbe

                100%

                CRF11

                CRF01_AE

                CRF02

                URF

                06CMLPH19CM

                F

                Hx. Sex

                Limbe

                 

                CRF11

                CRF01_AE

                CRF02

                URF

                Pol Sequences

                        

                06CMLPH19CM

                F

                Hx. Sex

                Limbe

                99%

                CRF11

                CRF01_AE

                CRF02

                URF

                06CMLPH11TT

                F

                Hx. Sex

                Limbe

                 

                CRF11

                CRF01_AE

                CRF02

                URF

                06CMLPH17HT

                M

                Hx. Sex

                Limbe

                99%

                CRF02

                CRF02

                CRF02

                CRF02

                06CMBDHS024

                F

                Hx.Sex

                Buea

                 

                F2

                CRF02

                F2

                URF*

                Env Sequences (gp41)

                        

                06CMLPH02MG

                F

                Hx. Sex

                Limbe

                97-99%

                CRF02

                CRF02

                CRF02

                CRF02

                06CMLPH17HT

                M

                Hx. Sex

                Limbe

                 

                CRF02

                CRF02

                CRF02

                CRF02

                06CMBDHS019

                F

                Hx. Sex

                Buea

                99%

                F2

                F2

                F2

                F2

                06CMBDHS024

                F

                Hx.Sex

                Buea

                 

                F2

                CRF02

                F2

                URF*

                Phylogenetically associated sequences are in rows for p17, pol and Env gp41 with Bootstrap values indicated. Columns indicate demographics and genotype. Patient IDs marked (*) demonstrate the emergence of URF’s within the population or that potentially had a common source of infection.

                Hx: Heterosexual, *pol gene has CRF02_AG

                Discussion

                The present study reveals the ongoing genetic diversity of HIV-1 in three cities Bamenda in the Northwest and Buea and Limbe in the Southern provinces of Cameroon based on genotyping of samples collected from 2006-2008. Even though these samples may not reflect the entire Cameroon population this study highlights the importance and dynamic nature of HIV evolution in this region. Viral diversity and drug resistance was observed in samples from both blood banks and other clinical sites. Subtype determination based on nucleotide sequence analysis of three distinct regions of the HIV-1 genome provides more detailed information of the phylogenetics of the HIV-1 epidemic in a specific region. In this study 66% of patients and blood donors studied harbored the CRF02_AG strain. Similar studies conducted on samples collected during the early part of the past decade showed that CRF02_AG was dominant in blood donors in Cameroon along with other HIV subtypes and CRFs [36]. It has been reported that CRF02_AG appeared to be stable in blood donors in Yaounde over the period of 1996-2004 [12] and this strain may have a higher fitness than other strains circulating in the country with high viral load and higher infectivity over other forms of HIV [37]. It is interesting to note that 26% of strains were URFs of CRF02_AG with existing subtypes F, B, D, G and CRF 11, CRF 06. Circulation of such HIV variants may be a factor in the evolution of the phylogenetic nature of the epidemic in this geographic region. Further longitudinal studies are needed in these areas to monitor HIV evolution, virus genetic, diversity and its immunologic impact. Host genetic factors that may contribute to the genetic diversity in this region may also be worthy of investigation and could provide new insights into HIV evolution. As noted earlier, the expanding genetic diversity raises public health concerns including the ability of diagnostic assays to detect these unique HIV mosaic variants.

                In an earlier study [38] it was observed that a small number of CRFs yielded discordant results with licensed assays, an observation consistent even with the plasma samples collected during 2007-2009 (unpublished data) highlighting the need for continued monitoring of variants and their impact on diagnostic assay sensitivity.

                Growth Kinetics

                The replication characteristics of the viruses were examined by performing co-cultivation studies with primary PBMCs. Viruses were classified as fast, slow and non replicating viruses. The majority of the viruses yielded high levels of HIV p24 antigen in cell culture, however some viruses yielded low levels or did not replicate. Most importantly, in our study we observed high levels of p24 antigen production with recombinants of CRF02_AG that contained URFs of the pol region of CRF01_AE, CRF_ 22 or subtype D when compared with recombinants that had a primary subtype F2 with CRF02_AG in the pol region. These findings suggest that the generation of new recombinants may be accompanied by variations in replication characteristics of the new strains which in turn may have an impact on virus transmission in this population.

                Drug Resistance

                Our next effort was to determine whether the available therapeutic options could be affected by emerging recombinant HIV strains. Among the 29% of patients that received ART, 55.5% had drug specific mutations. Most patients received NRTI/NNRTI standard combinations for the duration of 1-2 years at the time of sampling and very few received single dose Nevirapine or AZT to reduce parent-to-child transmission. Four patients (06CMBDSH05, 06CMARC007, ARC88 and ARC140) had resistance for all classes of RT antiretroviral therapy (Table 3) and the partial genotype of these isolates was CRF02_AG that contained URFs. Another two individuals (06CMLPH20SL and 06CMBDSH019) were on standard ART regimens available in Cameroon. Drug resistance profiles of the Cameroonian population from earlier studies had shown the presence of drug resistance associated with lamivudine efavirenz, and nevirapine [39, 40]. These drugs are widely used in Cameroon in either individual formulations or fixed-dose combinations. The fixed-dose combination of lamivudine/stavudine/nevirapine is now the most frequently prescribed drug in Cameroon and other African countries [41]. Since these resistance mutations were detected among patients with diverse strains we hypothesize that drug-related selection pressures may also be a contributing factor for viral evolution.

                Other NNRTI single mutations detected among patients on therapy include G190A, V118I, V179E, K219Q and H221K and these unusual mutations may be polymorphisms for the CRF02_AG or CRF02_AG containing URFs. Follow up studies are needed to provide more information on the implications of these mutations for pathogenesis and treatment. However, it has been reported that G190A mutation alone would decrease the susceptibility to nevirapine [42] and its presence as polymorphisms would impact prevention measures for mother-to-child transmission based on the drug.

                Interestingly 19/43 (44%) of drug naïve patients had drug resistance or polymorphisms at drug resistance sites. These findings suggest that resistant viruses were being transmitted within the study group. Detailed analysis of resistant codons (Table 3) 8/19 (42%) showed RTI associated mutations. Among drug naïve patients, one patient (06CMLPH20SL) had multidrug resistance for all classes of RTIs and another 6 patients had mutations that confer resistance to RT and protease drugs (Table 3). Such individuals pose a major concern for antiretroviral therapies provided by public health prevention programs in the country. These studies also highlight the importance of drug resistance testing prior to initiation of therapy.

                In the present study two individuals (Table 3) had point mutations for protease drug who had never received these drugs. A mutation at I54L reduces the susceptibility for fosamprenavir (FPV), lopinavir (LPV) and darunavir (DRV) but not Tipranavir (TPV). These mutations mostly occur in patients receiving these drugs but their presence as polymorphisms in patients with CRF02_AG genotype limits future use of these drugs. In Cameroon these mutations appear to be prevalent among drug naïve individuals [43, 44]. These observations suggest that they would have been transmitted with mutations for protease drug or that CRF02_AG also had natural polymorphism at these positions.

                All results were from random sampling at one single time point. In the future, linked studies will be required to determine the importance of emerging drug resistance in the regions studied.

                Genetic variation and phylogenetic relatedness

                The identification of divergent recombinant strains in three cities in Cameroon is consistent with findings reported by earlier investigators, we wished to examine whether specific segments of the HIV genome are phylogenetically associated with high bootstrap values within the population. Analysis of sequence similarity within the population in the p17/pol/gp41 region of two pairs of sequences showed that in each of them p17/pol/gp41 were associated in only 2 of the 3 genomic regions. The bootstrap values for these associations were 97-100% similar to values observed in direct transmission cases such as intravenous drug users [45] or mother to child transmission [46] In our study we observed high bootstrap values for some viruses suggesting that perhaps such associations may exist in specific cases. In particular one isolate (06CMBDHS024) that was primarily subtype F2 contained a pol segment of CRF02_AG, and when further analyzed this virus was closely associated in the pol region with the second isolate (06CMLPH17HT). These findings suggest epidemiological associations between them and it should also be noted that these two isolates were from two different cities. Extensive molecular epidemiological analysis linked with behavioral studies may provide a new approach for determining the public health significance of the emergence of new URFs in regions where multiple strains circulate.

                In conclusion, our study suggests that the genetic diversity of the HIV epidemic in Cameroon is evolving and periodic monitoring of HIV variants is necessary to determine the extent of virus evolution in this region. These studies are important as strains identified first in Cameroon and West Central Africa including CRF02_AG and CRF01_AE have eventually been transported and become prevalent in other parts of the world through globalization. It is also necessary to study genetic variation and understand its impact on licensed diagnostic and nucleic acid monitoring tests. Finally, the identification of drug resistance in drug naïve patients highlights the need to monitor viral genotype before treatment and after ART failure. A comprehensive genetic analysis of, and surveillance for, emerging HIV variants in major cities and rural areas on a periodic basis is clearly warranted in these regions of world. The insights gained from these studies will help us identify diagnostic, therapy and vaccine strategies associated with the discoveries of new strains that could successfully bolster the fight ongoing against HIV/AIDS.

                Declarations

                Acknowledgements

                The authors wish to acknowledge Drs. Xue Wang and Krishnakumar Devadas and Hira Nakhasi for review of the manuscript. The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.

                Authors’ Affiliations

                (1)
                Lab of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration
                (2)
                Department of Pathology, NYU School of Medicine

                References

                1. Mbopi Kéou FX, Mpoudi-Ngollé E, Nkengasong J, Zekeng L, Mbanya D, Affana G, Mauclère P, Monny Lobé M, Tapko JB, Ndumbe P, Salla R, Kaptué L, Bélec L: Trends of AIDS epidemic in Cameroon, 1986 through 1995. J Acquir Immune Defic Syndr Hum Retrovirol 1998,18(1):89–91.PubMedView Article
                2. Nkengasong JN, Janssens W, Heyndrickx L, Fransen K, Ndumbe PM, Motte J, Leonaers A, Ngolle M, Ayuk J, Piot P, et al.: Genotypic subtypes of HIV-1 in Cameroon. AIDS 1994,8(10):1405–12.PubMedView Article
                3. Mbanya D, Sama M, Tchounwou P: Current status of HIV/AIDS in Cameroon: how effective are control strategies? Int J Environ Res Public Health 2008,5(5):378–83.PubMedView Article
                4. UNAIDS/WHO AIDS Epidemic Update 2007.
                5. Ndembi N, Abraha A, Pilch H, Ichimura H, Mbanya D, Kaptue L, Salata R, Arts EJ: Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol 2008,46(1):177–84. Epub 2007 Sep 12PubMedView Article
                6. Turriziani O, Russo G, Lichtner M, Stano A, Tsague G, Maida P, Vullo V, Antonelli G: Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon. AIDS Res Hum Retroviruses 2008,24(6):781–5.PubMedView Article
                7. Fonjungo PN, Mpoudi EN, Torimiro JN, Alemnji GA, Eno LT, Nkengasong JN, Gao F, Rayfield M, Folks TM, Pieniazek D, Lal RB: Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon. AIDS Res Hum Retroviruses 2000,16(13):1319–24.PubMedView Article
                8. Yao JosephDC, Germer JeffreyJ: Plasma Load Discrepancies between the Roche Cobas Amplicor Human Immunodeficiency Virus Type 1 (HIV-1) Monitor Version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Assays. J Clin Microbiol 2008,46(2):834.PubMedView Article
                9. Plantier Jean-Christophe, Leoz Marie, Dickerson JonathanE, De Oliveira Fabienne, ois Cordonnier Franc¸, Leme´e Ve´ronique, Damond Florence, Robertson DavidL, Simon Franc¸ois: A new human immunodeficiency virus derived from gorillas. NATURE MEDICINE published online 2 August 2009
                10. Peeters M, Gueye A, Mboup S, Bibollet-Ruche F, Ekaza E, Mulanga C, Ouedrago R, Gandji R, Mpele P, Dibanga G, Koumare B, Saidou M, Esu-Williams E, Lombart JP, Badombena W, Luo N, Vanden Haesevelde M, Delaporte E: "Geographical distribution of HIV-1 group O viruses in Africa". AIDS 1997,11(4):493–8.PubMedView Article
                11. Yamaguchi Julie, Coffey Ruthie, Vallari Ana, Ngansop Charlotte, Mbanya Dora, Ndembi Nicaise, Kaptué Lazare, Gürtler LutzG, Bodelle Pierre, Schochetman Gerald, Devare SushilG, Brennan CatherineA: "Identification of HIV Type 1 Group N Infections in a Husband and Wife in Cameroon: Viral Genome Sequences Provide Evidence for Horizontal Transmission". AIDS Research and Human Retroviruses 2006,22(1):83–92.PubMedView Article
                12. Brennan CA, Bodelle P, Coffey R, Devare SG, Golden A, Hackett J Jr, Harris B, Holzmayer V, Luk KC, Schochetman G, Swanson P, Yamaguchi J, Vallari A, Ndembi N, Ngansop C, Makamche F, Mbanya D, Gürtler LG, Zekeng L, Kaptué L: The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J Acquir Immune Defic Syndr 2008,49(4):432–9.PubMedView Article
                13. Powell R, Barengolts D, Mayr L, Nyambi P: The Evolution of HIV-1 Diversity in Rural Cameroon and its Implications in Vaccine Design and Trials. Viruses 2010,2(2):639–654.PubMedView Article
                14. Carr JK, Wolfe ND, Torimiro JN, Tamoufe U, Mpoudi-Ngole E, Eyzaguirre L, Birx DL, McCutchan FE, Burke DS: HIV-1 recombinants with multiple parental strains in low-prevalence, remote regions of Cameroon: evolutionary relics? Retrovirology 2010, 7:39.PubMedView Article
                15. Soares EA, Makamche MF, Siqueira JD, Lumngwena E, Mbuagbaw J, Kaptue L, Asonganyi T, Seuánez HN, Soares MA, Alemnji G: Molecular diversity and polymerase gene genotypes of HIV-1 among treatment-naïve Cameroonian subjects with advanced disease. J Clin Virol 2010,48(3):173–9.PubMedView Article
                16. Machuca A, Tang S, Hu J, Lee S, Wood O, Vockley C, Vutukuri SG, Deshmukh R, Awazi B, Hewlett I: Increased genetic diversity and intersubtype recombinants of HIV-1 in blood donors from urban Cameroon. J Acquir Immune Defic Syndr 2007,45(3):361–3.PubMedView Article
                17. Nyambi P, Zekeng L, Kenfack H, Tongo M, Nanfack A, Nkombe I, Ndonko F, Shang J, Burda S, Mbah H, Agyingi L, Zhong P, Nádas A, Zolla-Pazner S, Marmor M: HIV infection in rural villages of Cameroon. J Acquir Immune Defic Syndr 2002,31(5):506–13.PubMedView Article
                18. Zhao J, Tang S, Ragupathy V, Carr JK, Wolfe ND, Awazi B, Hewlett I: Identification and genetic characterization of a novel CRF22_01A1 recombinant form of HIV type 1 in Cameroon. AIDS Res Hum Retroviruses 2010,26(9):1033–45.PubMedView Article
                19. Carr JK, Torimiro JN, Wolfe ND, Eitel MN, Kim B, Sanders-Buell E, Jagodzinski LL, Gotte D, Burke DS, Birx DL, McCutchan FE: The AG recombinant IbNG and novel strains of group M HIV-1 are common in Cameroon. Virology 2001,286(1):168–81.PubMedView Article
                20. Carr JK, Laukkanen T, Salminen MO, Albert J, Alaeus A, Kim B, Sanders-Buell E, Birx DL, McCutchan FE: Characterization of subtype A HIV-1 from Africa by full genome sequencing. AIDS 1999,13(14):1819–26.PubMedView Article
                21. Zemele P, Njouom R, Dasquier C, Njayou M, Izopet J, Puel J: International Conference on AIDS. Prevalence of HIV-1subtype A in Cameroon. Int Conf AIDS 2000., 13: abstract no. MoPeA2079
                22. Carr JK, Salminen MO, Albert J, Sanders-Buell E, Gotte D, Birx DL, McCutchan FE: Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology 1998,247(1):22–31.PubMedView Article
                23. Konings FA, Burda ST, Urbanski MM, Zhong P, Nadas A, Nyambi PN: Human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02_AG (CRF02_AG) has a higher in vitro replicative capacity than its parental subtypes A and G. J Med Virol 2006,78(5):523–34.PubMedView Article
                24. Njai HF, Gali Y, Vanham G, Clybergh C, Jennes W, Vidal N, Butel C, Mpoudi-Ngolle E, Peeters M, Ariën KK: The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology 2006, 3:40.PubMedView Article
                25. Powell RL, Zhao J, Konings FA, Tang S, Nanfack A, Burda S, Urbanski MM, Saa DR, Hewlett I, Nyambi PN: Identification of a novel circulating recombinant form (CRF) 36_cpx in Cameroon that combines two CRFs (01_AE and 02_AG) with ancestral lineages of subtypes A and G. AIDS Res Hum Retroviruses 2007,23(8):1008–19.PubMedView Article
                26. Powell RL, Zhao J, Konings FA, Tang S, Ewane L, Burda S, Urbanski MM, Saa DR, Hewlett I, Nyambi PN: Circulating recombinant form (CRF) 37_cpx: an old strain in Cameroon composed of diverse, genetically distant lineages of subtypes A and G. AIDS Res Hum Retroviruses 2007,23(7):923–33.PubMedView Article
                27. Konings FA, Haman GR, Xue Y, Urbanski MM, Hertzmark K, Nanfack A, Achkar JM, Burda ST, Nyambi PN: Genetic analysis of HIV-1 strains in rural eastern Cameroon indicates the evolution of second-generation recombinants to circulating recombinant forms. J Acquir Immune Defic Syndr 2006,42(3):331–41.PubMedView Article
                28. Preston BD, Poiesz BJ, Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science 1988,242(4882):1168–71.PubMedView Article
                29. Fang G, Weiser B, Kuiken C, Philpott SM, Rowland-Jones S, Plummer F, Kimani J, Shi B, Kaul R, Bwayo J, Anzala O, Burger H: Recombination following superinfection by HIV-1. AIDS 2004,18(2):153–9.PubMedView Article
                30. Kongnyuy EJ, Wiysonge CS, Mbu RE, Nana P, Kouam L: Wealth and sexual behaviour among men in Cameroon. BMC Int Health Hum Rights 2006, 6:11.PubMedView Article
                31. HIV sequence database web site use [http://​www.​hiv.​lanl.​gov]
                32. Zhang M, Huang Q, Huang Y, Wood O, Yuan W, Chancey C, Daniel S, Rios M, Hewlett I, Clouse KA, Dayton AI: beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL. Retrovirology 2008, 5:82.PubMedView Article
                33. Kumar S, Nei M, Dudley J, Tamura K: MEGA: A biologist-centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform 2008,9(4):299–306.PubMedView Article
                34. Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007,24(8):1596–1599.PubMedView Article
                35. Rhee Soo-Yon, Gonzales MatthewJ, Kantor Rami, Betts BradleyJ, Ravela Jaideep, Shafer RobertW: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 2003,31(1):298–303.PubMedView Article
                36. Nyambi P, Heyndrickx L, Vereecken K, Burda S, De Houwer K, Coppens S, Urbanski M, Williams C, Ndumbe P, Janssens W: Predominance of infection with HIV-1 circulating recombinant form CRF02_AG in major Cameroonian cities and towns. AIDS 2002,16(2):295–6.PubMedView Article
                37. Fischetti Lucia, Opare-Sem Ohene, Candotti Daniel, Lee Helen, Jean-Pierre Allain: Higher viral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana. AIDS 2004, 18:1203–1216.View Article
                38. Lee S, Wood O, Tang S, Hu J, Machuca A, Kerby S, Awazi B, Vockley C, Hewlett I: Detection of emerging HIV variants in blood donors from urban areas of Cameroon. AIDS Res Hum Retroviruses 2007,23(10):1262–7.PubMedView Article
                39. Laurent C, Kouanfack C, Vergne L, Tardy M, Zekeng L, Noumsi N, Butel C, Bourgeois A, Mpoudi-Ngolé E, Koulla-Shiro S, Peeters M, Delaporte E: Antiretroviral drug resistance and routine therapy, Cameroon. Emerg Infect Dis 2006,12(6):1001–4.PubMed
                40. Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N: Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther 2009,14(3):339–47.PubMed
                41. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E: Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004,364(9428):29–34.PubMedView Article
                42. Uhlmann ErikJ, Tebas Pablo, Storch GregoryA, Powderly WilliamG, Lie YolandaS, Whitcomb JeannetteM, Hellmann NicholasS, Arens MaxQ: Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. J Clin Virol 2004,31(3):198–203.PubMedView Article
                43. Jiang S, Xing H, Si X, Wang Y, Shao Y: Polymorphism of the protease and reverse transcriptase and drug resistance mutation patterns of HIV-1 subtype B prevailing in China. J Acquir Immune Defic Syndr 2006,42(4):512–4.PubMedView Article
                44. Konings FA, Zhong P, Agwara M, Agyingi L, Zekeng L, Achkar JM, Ewane L, Afane Ze E, Kinge T, Nyambi PN: Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res Hum Retroviruses 2004,20(1):105–9.PubMedView Article
                45. Nguyen L, Hu DJ, Choopanya K, Vanichseni S, Kitayaporn D, van Griensven F, Mock PA, Kittikraisak W, Young NL, Mastro TD, Subbarao S: Genetic analysis of incident HIV-1 strains among injection drug users in Bangkok: evidence for multiple transmission clusters during a period of high incidence. J Acquir Immune Defic Syndr 2002,30(2):248–56.PubMed
                46. Ramakrishnan R, Mehta R, Sundaravaradan V, Davis T, Ahmad N: Characterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission. Retrovirology 2006, 3:42.PubMedView Article

                Copyright

                © Ragupathy et al; licensee BioMed Central Ltd. 2011

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                Advertisement